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ABSTRACT
Therapeutic management of gastroenteropancreatic neuroendocrine tumors 
(GEP-NETs) is challenging. The mammalian target of rapamycin (mTOR) inhibitor 
everolimus recently obtained approval from the Food and Drug Administration for the 
treatment of patients with advanced pancreatic neuroendocrine tumors (pNETs). Despite 
its promising antitumor efficacy observed in cell lines, clinical benefit for patients is 
unsatisfactory. The limited therapeutic potential of everolimus in cancer cells has been 
attributed to Akt activation due to feedback loops relief following mTOR inhibition. 
Combined inhibition of Akt might then improve everolimus antitumoral effect. In this 
regard, the somatostatin analog (SSA) octreotide has been shown to repress the PI3K/
Akt pathway in some tumor cell lines. Moreover, SSAs are well tolerated and routinely 
used to reduce symptoms caused by peptide release in patients carrying functional 
GEP-NETs. We have recently established and characterized primary cultures of human 
pNETs and demonstrated the anti-proliferative effects of both octreotide and pasireotide. 
In this study, we aim at determining the antitumor efficacy of everolimus alone or in 
combination with the SSAs octreotide and pasireotide in primary cultures of pNETs. 
Everolimus reduced both Chromogranin A secretion and cell viability and upregulated 
Akt activity in single treatment. Its anti-proliferative and anti-secretory efficacy was not 
improved combined with the SSAs. Both SSAs did not overcome everolimus-induced Akt 
upregulation. Furthermore, caspase-dependent apoptosis induced by SSAs was lost in 
combined treatments. These molecular events provide the first evidence supporting the 
lack of marked benefit in patients co-treated with everolimus and SSA.
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INTRODUCTION
Gastroenteropancreatic (GEP) neuroendocrine 
tumors (NETs) is a rare and heterogeneous group of 
tumors, with recent increased incidence and prevalence 
[1]. Pancreatic neuroendocrine tumors (pNETs) constitute 
a distinct subset of GEP-NETs which behave and respond 
to systemic treatments differently to other GEP-NETs (see 
[2] for a review). The majority of pNETs are sporadic but 
some are associated with inherited genetic syndromes such 
as multiple endocrine neoplasia type 1 syndrome (MEN1) 
and tuberus sclerosis. They are classified as functional (10-
30%) or non functional (50-80%), based on their specific 
pancreatic hormone hypersecretion [3]. Treatment options 
range from curative surgery for localized resectable 
disease to palliation with medical therapies including 
somatostatin analogs (SSAs), chemotherapy and targeted 
treatments for advanced and metastatic pNETs [4]. The 
SSAs octreotide and lanreotide are currently used to reduce 
symptoms caused by peptides release in a majority of 
patients carrying functional GEP-NETs [5]. These effects 
have been credited to their binding to the somatostatin 
receptor subtype 2 (SST2). SSAs anti-proliferative role has 
been investigated in PROMID and CLARINET studies. 
Both long acting octreotide and lanreotide significantly 
prolonged progression free survival (PFS) respectively in 
patients with well-differentiated metastatic midguts GEP-
NETs and metastatic pNETs [6, 7].
The PI3K/Akt/mTOR pathway integrates growth 
factor signals and plays a central role in regulating 
multiple cellular processes such as cell growth, survival 
and protein synthesis. Several studies have suggested the 
involvement of this pathway in pNET tumorigenesis and 
progression. Whole exome sequencing of pNETs identified 
inactivating mutations of two major negative regulators 
of the PI3K/Akt/mTOR pathway, the phosphatase and 
tensin homolog (PTEN) and the tuberous sclerosis 2 
(TSC2), in 14% of tumors [8]. Moreover, Missiaglia et 
al. have shown that PTEN and TSC2 downregulation 
was associated with shorter PFS and overall survival of 
pNETs patients [9]. On the contrary, activated levels of 
Akt and mTOR have been observed in a subset of pNETs 
but without significant correlation with clinicopathological 
features [10–12]. Overall, these clues have given the 
rational for the use of mTOR inhibitors in the treatment of 
pNETs. Everolimus, a mTORC1 inhibitor, induces anti-
proliferative effects in the pNET cell line BON [13]. In 
the phase III RADIANT 3 trial, everolimus significantly 
prolonged PFS in patients with progressive advanced 
pNETs compared with placebo [14]. Thus everolimus 
obtained approval from the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for 
the treatment of patients with advanced pNETs and more 
recently, for NETs of gastrointestinal or lung origin. 
However, disease stabilization is observed rather than 
objective response, which remains low (<5%). The modest 
antitumor activity of everolimus observed in clinical 
trials may be due to feedback mechanisms favoring pro-
survival signals. The loss of S6kinase-dependent negative 
feedback loop, involving expression of the insulin receptor 
substrate 1 (IRS-1), leading to the activation of PI3K/Akt 
and Ras/MAPKinase has been observed in breast cancer 
cell lines and human breast and colorectal carcinomas 
after everolimus treatment [15, 16]. Therefore, combined 
treatments with drugs targeting PI3K/Akt could improve 
the anti-proliferative effect of everolimus. In this regard, 
activation of SST2 has been shown to repress PI3K 
activity by disrupting the interaction between SST2 and 
the p85 PI3K regulatory subunit in pituitary and pancreatic 
adenocarcinoma cell lines [17, 18]. Clinical benefits of 
combined everolimus with octreotide have been evaluated 
in pNETs in a phase II trial. Concomitant treatment of 
everolimus and octreotide increased PFS in comparison 
with everolimus alone, however objective response rate 
was lesser in combined treatment [19].
We have recently established and characterized 
primary cultures of human pNETs and demonstrated the 
anti-proliferative effects of both octreotide and pasireotide 
[20]. To assess the relevance of everolimus and co-
treatments in pNETs, we have used this suitable state-of-
the-art preclinical model to evaluate the anti-proliferative 
and anti-secretory effects of everolimus in single treatment 
or in combination with the SSAs octreotide and pasireotide 
from 25 well characterized tumors. The role of PI3K/Akt/
mTOR and the MAPKinase ERK1/2 signaling pathways 
under these treatments has also been monitored.
RESULTS
Molecular characteristics of pNET tissues and 
pNET primary cultures
Mutations of MEN1, DAXX/ATRX, PTEN or 
down regulation of their respective proteins have been 
frequently observed in pNETs ([8, 9]. Loss of DAXX/
ATRX expression has recently been associated with 
poor prognosis and might be used to refine prognostic 
classification [21]. PTEN mutations have been associated 
with rapamycin sensitivity in different cell lines [22]. 
In this context, to better characterize patients’ tumors, 
we searched for MEN1 mutations from formalin-fixed 
paraffin-embedded tissue sections (FFPE) (Table 1). 
PTEN, DAXX and ATRX expression was performed by 
using immunohistochemistry (IHC) (Table 1). MEN1 
mutations were frequently observed in 68% of the tumors 
(17/25). PTEN was always found expressed but with 
varying levels. Low PTEN expression was observed in 
28% of the tumors (7/25). ATRX or DAXX expression 
was lost in 29% of the tumors (7/24). A similar frequency 
has been obtained by Singhi et al. in a large series of 
pNETs [21]. We did not observe any correlation between 
PTEN, MEN1 and DAXX/ATRX alterations (not shown), 
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neither between DAXX/ATRX loss and the initial grade 
of the tumor (p=0.093). However, DAXX/ATRX was 
lost in 3 out of the 4 grade 3 tumors present in our series 
(Table 1).
We have previously shown that pNET cells 
in primary culture maintained their neuroendocrine 
characteristics. In particular, the majority of cells 
expressed chromogranin A (CgA) and the SST2 receptor. 
Moreover we observed that their capacity to secrete CgA 
was regulated by SSAs [20]. Thus we determined the 
level of SST2 mRNA expression, CgA secretion and its 
sensitivity to octreotide in the primary cultures of our 
series (Table 2). We detected SST2 mRNA expression in 
all the primary culture analyzed. As previously observed 
SST2 expression level was higher than the other SST 
subtypes (not shown). We detected CgA secretion in 
all investigated primary cultures with variable levels. 
Moreover, except in one primary culture (tumor 2), CgA 
secretion was significantly decreased by 1nM octreotide 
(Table 2).
Table 1: Molecular characteristics of human pNET tissues
tumor 
(number)
Grade MEN1 (tumoral mutation) PTEN IHC ATRX IHC DAXX IHC
1 G2 No 1(h) N P
2 G1 No 3 P P
3 G2 exon 10 deleted 3 P P
4 G1 Exon 4 : c.660G>A (p.Trp220*) 2 P NA
5(a) G2 Exon 2 : c.249_252del (p.Ile85Serfs*33) 2 P P
6 G3 No 3(h) P P
7 G1 Exon 3 : c.586G>A (p.Val196Ile) 3 P P
8 G2 Exon 9 : c.1226G>A (p.Cys409Tyr) 3(h) P N
9 G2 Exon 2 : c.244G>C (p.Asp82His) 2 P N
10 G2 Exon 5 : c.833T>C (p.Met278Thr) 3 P P
11 G2 Exon 8 : c.1151A>G p.Glu384Lys 3 P P
12 G2 Exon 3 : c.456T>G (p.Leu152Phe) 1(h) P NA
13 G2 No 3 P P
14 G2 Exon 3 : c.526G>A (p.Ala176Thr) 2 P P
15 G3 Exon 3 : c.487G>A (p.Gly163Arg)Exon 10 : c.1741G>A (p.Ala581Thr) 1 NA N
16 G2 Exon7 : c.1034C>T p.Ala345Val 1(h) P P
17 G2 No 3 P P
18 G2 Exon 2: c.38T>C (p.Leu13Pro)Exon 9: c.1318C>T (p.Leu440Phe) 1(h) NA NA
19 G1 Exon2: c.322C>T (p.Arg108*) 1(h) P P
20(a) G1 Exon 7c.1049C>T 2(h) P N
21 G1 No 3 P P
22 G1 No 3 P P
23 G3 Exon 2 c.244G>C (p.Asp82His)Exon 3: c.514G>A (p.Asp172Asn) 3 P N
24 G3 Exon 3 : c.514G>A (p.Asp172Asn) 1(h) N P
25 G2 No 2 NA P
IHC (immunohistochemistry). (a) MEN1 syndrome, mutation found at the germinal level and in the tumor. (h) 
Heterogeneous labeling. 1-3: low to high labeling level. N (negative labeling). P (positive labeling). NA (not available).
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Effects of everolimus on cell viability
We first examined a dose effect of everolimus 
treatment for 72h ranging from 0.1nM to 10nM on cell 
viability of 3 pNETs primary cultures. Everolimus 
significantly reduced viable cell number at both 1 and 
10nM with maximal effect observed for 1nM (Figure 1A). 
We then tested the effect of 1nM everolimus during 72h, 
in the primary cultures from 22 pNETs. This concentration 
is approximately the blood concentration of everolimus 
(range 2.7-95 nM) measured after 24h treatment of 
patients with 5-10mg per day [23, 24]. Everolimus 
decreased viable cell number from 14 % to 77 % of 
control value in 20 primary cultures (Figure 1B) with a 
median value of 59.3% (Figure 1C). Cell viability was not 
significantly altered in 2 primary cultures (90 ± 12% of 
control value; Figure 1B). No correlation was observed 
between cell viability inhibition by everolimus and the 
WHO grade or Ki67 index of the initial tumor (R=-0.207, 
p= 0.355; R=- 0.122, p=0.590 respectively). However, cell 
viability was repressed from 40 to 58% by everolimus in 
4 out of 6 tested tumors with a Ki67≥10% (two grade 3 
Table 2: Molecular characteristics of pNET primary cultures
Tumor (number) Grade SST2R (copies/
copies GUSβ)
CgA secretion
Control (U/l) octreotide (%inhibition)
1 G2 2.80 325 ± 9 28 ± 1**
2 G1 4.94 170 ± 5 8 ± 5
3 G2 1.57 159 ± 1 49 ± 10*
4 G1 6.67 3941 ± 13 51 ± 4**
5 G2 ND ND ND
6 G3 0.32 10 ± 1 44 ± 7*
7 G1 5.08 137 ± 6 93 ± 1***
8 G2 0.96 49 ± 1 34 ± 11*
9 G2 1.62 40 ± 2 39 ± 2**
10 G2 0.50 488 ± 10 72 ± 1*
11 G2 0.53 21 ± 2 37 ± 6*
12 G2 2.23 514 ± 11 71 ± 1***
13 G2 0.88 870 ± 125 63 ± 2**
14 G2 2.75 569 ± 48 16 ± 2*
15 G3 7.62 284 ± 13 93 ± 2**
16 G2 0.96 691 ± 87 76 ± 10*
17 G2 3.65 93 ± 19 47 ± 6*
18 G2 3.94 66 ± 2 36 ± 4**
19 G1 2.35 735 ± 33 36 ± 15*
20 G1 ND ND ND
21 G1 3.23 16 ± 2 49 ± 9*
22 G1 2.67 568 ± 21 85 ± 1***
23 G3 1.11 ND ND
24 G3 0.50 ND ND
25 G2 6.92 ND ND
SST2 receptor mRNA was determined as described in patients and methods by real-time PCR. Cells were treated in the 
absence or in the presence of 1nM octreotide and CgA secretion was measured as described in patients and methods. (*) 
p<0.05; (**) p<0.01 (***) p<0.001 versus control conditions.
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Figure 1: Everolimus decreases cell viability in primary cultures of human pNETs. (A) Primary culture cells from 3 pNETs 
(tumors 2,10,11) were incubated without (vehicle with 106 fold DMSO dilution) and with 0.1-10 nM everolimus for 72 h and cell viability 
was determined as described in patients and methods. Results are expressed as mean ± SEM (n=3) in percent of control. Each assay was 
performed in triplicate. (**) p<0.01; (°°) p<0.01 versus control. (B) Cell viability determined as in A in primary culture cells from 22 pNETs 
incubated without (vehicle) and with 1 nM everolimus for 72 h. (NS = not significant). (C) Cell viability determined in B in the primary 
cultures of the 20 pNETs responsive to 1nM everolimus. The horizontal bar represents the median.
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with Ki67≥ 45%). In the same way, no correlation was 
observed between cell viability inhibition by everolimus 
and the presence of MEN1 tumor mutations or PTEN, 
DAXX/ATRX expression levels.
Effects of everolimus on CgA secretion
In the same 3 pNETs primary cultures described 
above, everolimus significantly decreased CgA secretion 
with the same efficacy regardless the concentration (Figure 
2A). Among the 19 primary cultures analyzed, 1nM 
everolimus reduced CgA secretion from 13 % to 61 % of 
the control value in 12 primary cultures of pNETs with a 
median value of 43.3% (Figure 2B, 2C). CgA secretion 
was not significantly modified under 1nM everolimus 
treatment in the primary cultures from 7 tumors (median 
value = 92.2% of control) (Figure 2B, 2C). There was no 
correlation between everolimus inhibitions observed on 
cell viability and on CgA secretion (R=0.036, p=0.883). 
No correlation was observed between the inhibition of 
CgA secretion by everolimus and the WHO grade or Ki67 
index of the initial tumor (R=0.237, p= 0.328; R=0.134, 
p=0.584 respectively). However, CgA secretion was 
repressed from 37 to 69% by everolimus in 4 out of 5 
tested tumors with a Ki67≥10% (two grade 3 with Ki67≥ 
45%). Moreover, no correlation was observed between 
CgA inhibition by everolimus and the presence of MEN1 
tumor mutations or PTEN, DAXX/ATRX expression 
levels.
Effects of everolimus and SSAs in combination, 
on cell viability and caspase activities
We have previously shown that, at clinically 
relevant concentrations [25, 26], both octreotide and 
pasireotide repressed hormonal secretion and cell 
viability in established pNETs primary cultures [20]. We 
then tested combined treatment of everolimus and SSAs, 
on cell viability in 19 pNETs responsive to everolimus 
in primary cultures. As previously described [20], 72h 
exposure to 1nM octreotide or 1nM pasireotide reduced 
cell viability with no significant difference between both 
analogs (Figure 3A, 3B, 3C). We have previously shown 
a strong correlation between the effects of octreotide 
and pasireotide on cell viability. A slight correlation 
was observed between everolimus and octreotide effects 
on cell viability whereas no correlation was observed 
between everolimus and pasireotide (R=0.492, p=0.044; 
R=0.217, p=0.402 respectively). No significant correlation 
was observed between the inhibition of cell viability by 
each SSA and the WHO grade or Ki67 index of the initial 
tumor (R< 0.07, p> 0.786 in the different cases). However, 
cell viability was largely repressed by octreotide, in 2 out 
of 5 tested tumors with a Ki67≥10% (by 53% in a grade 
2 tumor with a Ki67=10% and by 74% in a grade 3 tumor 
with Ki67= 90%). We did not observed any correlation 
between SSAs-induced cell viability inhibition and the 
presence of MEN1 tumor mutations or PTEN, DAXX/
ATRX expression levels.
Cells from the different pNETs did not respond 
similarly to combined treatments of 1nM everolimus with 
either 1nM octreotide or 1nM pasireotide. Everolimus-
induced inhibition of cell viability was increased in only 
one primary culture (from a grade 2 tumor with Ki67=3%; 
tumor n°8) under combined treatments (Figure 3A). 
Two types of response were observed for the other 18 
primary cultures. Cell viability was significantly inhibited 
whatever the treatment in 9 primary cultures, without 
significant difference between the different treatments, 
even in combination (Figure 3B). These primary cultures 
were from 2 grade 1 and 7 grade 2 tumors, with Ki67≥5% 
in 6 tumors. Cell viability was also significantly inhibited 
by single treatments in the remaining 9 primary cultures 
with a significantly higher sensitivity to everolimus than 
SSAs (p=0.02 and p=0.004 respectively for octreotide 
and pasireotide). Surprisingly, combined treatments of 
1nM everolimus with either 1nM octreotide or 1nM 
pasireotide, in these primary cultures, partially or fully 
reversed inhibition of cell viability induced by each single 
treatment (Figure 3C). Moreover, primary cultures of this 
group (Figure 3C) are significantly more responsive to 
everolimus than primary cultures responding similarly 
to each treatment (Figure 3B) (p< 0.02). These primary 
cultures were from 3 grade 1, 4 grade 2 and 2 grade 
3 tumors with Ki67≥5% in 5 tumors. There was no 
significant difference between the two type of response 
to combined treatments with respect to the grade or Ki67 
index of the initial tumor (p=0.999, p=0.746 respectively).
To elucidate the observed effects of everolimus 
alone or in combined treatment with the SSAs on cell 
viability, we determined the activation level of the 
executioner caspases 3/7. Basal caspase activities were 
not modified with 1nM everolimus treatment during 
24h whereas both 1nM octreotide and 1nM pasireotide 
significantly increased caspase activities as previously 
observed associated to an increase in the number of 
TUNEL positive cells ([20], Figure 3D). Caspase 
activities were not significantly triggered by combined 
treatments of 1nM everolimus with either 1nM octreotide 
or with 1nM pasireotide (Figure 3D). This suggests that 
everolimus repressed the activity of caspases induced by 
SSAs in single treatments. Caspase activities have been 
determined in 6 primary cultures. Five of them belong to 
primary cultures described in Figure 3C and one in Figure 
3B without difference in the response.
Effects of everolimus and SSAs in combination 
on CgA secretion
We next explored the effect of everolimus 
combined with the SSAs on CgA secretion from the 12 
pNETs responsive to everolimus in primary cultures. 72h 
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Figure 2: Effect of everolimus on CgA secretion in primary cultures of human pNETs. (A) Primary culture cells from 3 
pNETs (tumors 2,10,11) were incubated without (vehicle with 106 fold DMSO dilution) and with 0.1-10 nM everolimus for 72 h and CgA 
secretion was measured as described in patients and methods. Results are expressed as mean ± SEM (n=3) in percent of control. Each 
assay was performed in triplicate. (°°) p<0.01 versus control. (B) CgA secretion determined as in A in primary culture cells from 19 pNETs 
incubated without (vehicle) and with 1 nM everolimus for 72 h. (C) CgA secretion determined in B of the 12 pNETs primary cultures that 
were responsive to 1nM everolimus treatment and CgA secretion of the 7 pNETs primary cultures that were nonresponsive to everolimus 
treatment. The horizontal bars represent the medians.
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treatment of cells with 1nM octreotide or 1nM pasireotide 
alone similarly decreased CgA secretion as previously 
observed [20] (Figure 4A, 4B), except in one primary 
culture which do not respond to SSAs (tumor 2; Table 2). 
We did not observe any correlation between everolimus 
and octreotide or everolimus and pasireotide inhibition 
of CgA secretion (R=0.205, p=0.522; R=0.342, p=0.276 
respectively). Inhibition of CgA secretion by combined 
treatments was increased in only one primary culture (from 
a grade 1 tumor, with Ki67<2%; tumor 4) in comparison 
to everolimus or SSAs treatments alone (Figure 4A). We 
noticed that in this primary culture, combined treatments 
partially reverted cell viability inhibition induced by 
each single treatment. CgA secretion was significantly 
inhibited in the other 10 primary cultures whatever the 
treatment (Figure 4B). However no significant difference 
was observed between the different treatments, even in 
the combined treatments of 1nM everolimus with 1nM 
octreotide or 1nM pasireotide (Figure 4B). These 10 
primary cultures were from 2 grade 1, 6 grade 2 and 2 
grade 3 tumors with Ki67≥5% in 7 tumors. We did not 
observe any correlation between tumor grade, Ki67 
index, MEN1 tumor mutations or PTEN, DAXX/ATRX 
expression levels of the initial tumor and inhibition of CgA 
secretion by the different treatments (R< 0.156, p>0.109). 
These results suggested that although everolimus and 
SSAs reduced cell viability and CgA secretion in single 
treatments, treatment combinations did not achieve any 
beneficial impact except in two tumors (4, 8).
Modulation of PI3K/Akt and ERK1/2 pathways 
under everolimus and SSAs single treatments
It has been shown, in neuroendocrine cell lines 
or tumors, that everolimus and SSAs might control cell 
proliferation through the modulation of the PI3K/Akt/
mTOR and/or the MAPKinase ERK1/2 pathways. In 
this context, we first explored the phosphorylated level 
Figure 3: Cell viability and caspase activities in combined treatments of everolimus with SSAs. Primary culture cells from 
(A) one pNET (n°8), (B) 9 pNETs (N° 5,10-14,18-20) (C) 9 pNETs (n°1-4,6,7,9,15,17) were incubated for 72h in the absence (vehicle) or 
in the presence of 1nM everolimus (Eve), or 1nM octreotide (Oct), or 1nM pasireotide (Pas) alone (diluted in vehicle) or in the presence 
of everolimus and octreotide or everolimus and pasireotide as indicated in the figure. Cell viability was determined as described in patients 
and methods. Results are expressed as mean ± SEM ((A), n=1; (B,C) n=9) in percent of control. (D) Primary cultures from 6 pNETs (n°1-
3,7,9,18) were incubated for 24h in the absence (vehicle) or in the presence of 1nM everolimus and/or SSAs (diluted in vehicle) as indicated 
in the figure. Caspase activity was determined as described in patients and methods. Results are expressed as mean ± SEM (n=6) in percent 
of control. Each assay was performed in triplicate. (°) p<0.05; (°°) p<0.01 (°°°) p<0.001 versus control ; (**) p<0.01; (***) p<0.001, (ns) 
not significant.
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of key intermediates of both pathways under everolimus 
and SSAs single treatments. We assessed the effect of 
everolimus, inhibitor of mTORC1, on its downstream 
target phosphorylation, p70S6K. After 30 min and 24h of 
treatment with 1nM everolimus, p70S6K phosphorylation 
was largely decreased, confirming that pNETs cells in 
primary cultures are sensitive to everolimus (Figure 5A, 
5B). In these conditions, Akt phosphorylation was not 
modified during short treatment (30min), whereas it was 
increased after 24h of treatment (Figure 5A, 5B). Noted 
that although phospho-p70S6K was repressed, phospho-
Akt (P-Akt) was not increased after 24h of everolimus 
treatment in two of the seven pNETs analyzed (tumors 5, 
20). In addition, 1nM everolimus treatment did not alter 
ERK1/2 phosphorylation even after 24h of treatment 
(Figure 5A, 5B). Similarly, treatment of pNETs in 
primary cultures with 1nM octreotide or 1nM pasireotide 
during 30 min or 24h did not significantly modify the 
phosphorylation levels of p70S6K, Akt or ERK1/2 (Figure 
5C–5F). These results suggested that the SSAs did not 
modulate the activity of PI3K/Akt and ERK1/2 pathways 
in our experimental conditions.
Figure 4: CgA secretion in combined treatments of everolimus with SSAs. Primary culture cells from (A) one pNET (n°4), 
(B) 10 pNETs (n° 3,6-8,10,11,15-17,19) were incubated for 72h in the absence (vehicle) or in the presence of 1nM everolimus (Eve), or 
1nM octreotide (Oct), or 1nM pasireotide (Pas) alone (diluted in vehicle) or in the presence of everolimus and octreotide or everolimus and 
pasireotide as indicated in the figure. CgA secretion was determined as described in patients and methods. Results are expressed as mean ± 
SEM ((A) n=1; (B) n=10) in percent of control. Each assay was performed in triplicate. (°) p<0.05; (°°) p<0.01 (°°°) p<0.001 versus control 
; (***) p<0.001, (ns) not significant.
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Effects of everolimus and SSAs in combined 
treatments on PI3K/Akt and ERK1/2 pathways
We finally assessed the effects of combined 
everolimus and SSAs treatments on PI3K/Akt and ERK1/2 
pathways. Combined treatments of 1nM everolimus and 
1nM octreotide or 1nM pasireotide during 24h significantly 
inhibited p70S6K phosphorylation compared to control or 
SSAs in single treatment. However, SSAs did not enhance 
everolimus-induced inhibition of p70S6K phosphorylation 
(p=0.125; p=0.875 respectively in the presence of octreotide 
plus everolimus and pasireotide plus everolimus; Figure 
6A, 6B). Likewise, combined treatments significantly 
increased P-Akt compared to control conditions or SSAs 
in single treatment (Figure 6A, 6C). However, P-Akt level 
was similar in both everolimus as single treatment or in 
combined treatments (p=0.796; p=0.750 respectively in the 
presence of octreotide plus everolimus and pasireotide plus 
everolimus). In the same conditions, drugs combination 
did not alter ERK1/2 phosphorylation (Figure 6A, 6D) as 
previously observed in the presence of each drug alone 
(Figure 5).
DISCUSSION
Therapeutic strategy in the management of advanced 
pNETs is still challenging. Despite promising efficacy 
of targeted therapies observed in cell lines, PFS and 
overall survival of patients in clinical trials are lower than 
Figure 5: Effects of everolimus and the SSAs single treatments on the activity of the PI3K/Akt and MAPKinase 
ERK1/2 pathways. Primary culture cells from pNETs were incubated 30 min (3 pNETs) or 24h in the absence ( vehicle) or in the 
presence of 1nM everolimus (Eve) (7 pNETs) (A, B) or 1nM octreotide (Oct) (5 pNETs) (C, D) or 1nM pasireotide (Pas) (5 pNETs) (E, 
F). The phosphorylated levels of p70S6K, Akt and ERK1/2 were analyzed by using western blotting as described in patients and methods. 
Representative immunoblots are given in (A), (C), (E). Means ± SEM in percent of control are given in (B), (D), (F) ((B) n=7; (D,F) 
n=5). Control condition (white bars), 30min treatment (hatched bars), 24h treatment (black and grey bars). (°) p<0.05, (°°°) p<0.001versus 
control.
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expected, suggesting lack of relevant preclinical models. 
We recently established and characterized primary cultures 
of human pNETs and demonstrated the anti-secretory and 
anti-proliferative effects of both octreotide and pasireotide 
[20]. In this report, we show for the first time that the 
mTOR inhibitor everolimus reduces both CgA secretion 
and cell viability in human primary cultures from pNETs. 
Although everolimus and SSAs decrease cell viability and 
CgA secretion in single treatments, no benefit is observed 
from combined treatments. To further delineate the 
mechanisms contributing to these effects, we demonstrate 
that everolimus-induced decrease of cell viability is 
not due to caspase-dependent apoptosis. Moreover, in 
combined treatments, caspase activities induced by SSAs 
are reverted. Considering two main signaling pathways 
previously shown as involved in NETs tumorigenesis 
[27], we show that ERK1/2 pathway is not affected by 
everolimus or SSAs as single or combined treatments 
in pNETs primary cultures. However, everolimus 
hyperactivates Akt, whereas SSAs do not alter PI3K/
Akt/mTOR pathway. Moreover, in combined treatments, 
p70S6K activity is inhibited and Akt is as much activated 
as in the presence of everolimus alone.
The anti-proliferative effect of everolimus has been 
largely established in different NET cell lines [28–30] 
and particularly of pancreatic origin [13, 31, 32]. For the 
first time, we show that everolimus represses cell viability 
in the majority (90%) of primary cultures from human 
pNETs. The efficacy of everolimus is nevertheless variable 
and may correlate with the observations of the phase II and 
III clinical trials [14, 19] showing that partial or overall 
responses were rarely observed despite increase in PFS.
Beside the antitumoral management, control of 
hormone hypersecretion is required for up to 30% of 
patients with pNET. Advances in the control of hormone-
excess state have been recently reviewed [33]. Whereas 
somatostatin analogs are the first-line treatment in the 
majority of GEP-NET patients, everolimus has been 
shown effective at controlling hormone-excess symptoms 
in patients with insulinoma in case reports or in small 
series [34–37] and in patients with carcinoid syndrome 
[38]. In clinical trials, CgA blood level is commonly 
Figure 6: Effects of everolimus and the SSAs in combined treatments on the activity of the PI3K/Akt and MAPKinase 
ERK1/2 pathways. Primary culture cells from 4 pNETs were incubated for 24h in the absence (vehicle) or in the presence of 1nM 
everolimus (Eve), or 1nM octreotide (Oct), or 1nM pasireotide (Pas) alone (diluted in vehicle) or in the presence of 1nM everolimus and 
1nM octreotide or 1nM everolimus and 1nM pasireotide as indicated in the figure. The phosphorylated levels of p70S6K, Akt and ERK1/2 
were analyzed by using western blotting as described in patients and methods. Representative immunoblots are given in (A). Means ± SEM 
(n=4) in percent of control are given for p70S6K (B), Akt (C) and ERK2 (D). (*) p<0.05; (°) p<0.05 versus control.
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considered as a biomarker of NETs. An early decrease 
in CgA blood level in response to everolimus has been 
correlated with an increase in PFS. So this early CgA 
response might have a global predictive value [19]. 
Here we show that everolimus represses CgA secretion 
in 63% of the pNETs primary cultures. Since decrease 
in cell number by everolimus treatment should have an 
impact on CgA secretion, the level of CgA secretion has 
been normalized to the cell number. Moreover, there is 
no correlation between everolimus-induced inhibition 
of cell viability and CgA secretion, suggesting that 
everolimus inhibition of CgA secretion might be a direct 
effect on pNET cell secretion. The PI3K pathway has been 
identified as a potential regulator of peptide secretion in 
the pNET cell lines BON and QGP1 depending on the 
inhibitor used (PIK-75, BKM120 or BEZ235) and the 
peptide secreted (neurotensin, serotonin or CgA) [39, 40]. 
Inhibition of both PI3K and mTOR seems to be required 
to block peptide secretion [40]. In the primary cultures 
of pNETs, inhibition of mTOR seems to be sufficient to 
repress CgA secretion (see below). Inhibition of CgA 
secretion under everolimus treatment is of importance as 
it has been previously shown that CgA and some of its 
fragments induce cell proliferation of the small intestinal 
NET cell lines L-STS and H-STS through Akt/mTOR 
activation [41].
Akt activation following rapalogs treatments is 
commonly observed in cancer cells. This effect has been 
attributed to loss of physiological negative feedback 
loops on PI3K/Akt and MAPK pathways, limiting the 
anti-proliferative potential of these drugs [15, 16, 18]. 
Activation of Akt by rapalogs is not systematically 
observed in NET cell lines [13, 30–32]. In the present 
report, all pNETs primary cultures tested are sensitive 
to everolimus (using p70S6K inhibition as downstream 
marker of mTOR inhibition). P-Akt (ser473) is increased 
whereas activation of ERK1/2 is never observed. We 
noticed that P-Akt is not upregulated in two tumors (5, 
20). These observations indicate a specific upregulation of 
the PI3K/Akt pathway through loss of P70S6K/IRS-1 or 
P70S6K/mTORC2 negative feedbacks [15, 42]. In these 
conditions, everolimus does not induce caspase activity. 
This suggests that proapoptotic substrates downstream of 
both Akt and p70S6K, may be selectively phosphorylated 
and inactivated by Akt [43, 44]. Our results are in 
agreement with those of Valentino et al., showing an 
inverse correlation between Akt activation and apoptosis 
in BON and QGP1 cell lines [40]. Whereas everolimus 
induced both apoptosis and cell cycle arrest in cell 
lines [13, 45], its anti-proliferative effect occurs mainly 
through cell cycle arrest in the majority of NET cell lines 
[28, 30, 46]. This mechanism is likely predominant in 
primary cultures of pNETs and may contribute to disease 
stabilization observed in patients [14].
SSAs have a favorable safety profile in patients 
with NETs [6, 47]. Moreover, previous reports have 
shown that octreotide decreases PI3K/Akt pathway 
activity in pituitary and pancreatic adenocarcinoma cell 
lines [17, 18]. Since we have previously shown efficacy 
of SSAs in pNETs primary cultures [20], it was tempting 
to perform co-treatments of everolimus with SSAs to 
improve everolimus efficacy. Unfortunately, we cannot 
evidence any increase in either cell viability inhibition 
nor in the inhibition of CgA secretion in combined 
treatments (except in one pNET for each parameter 
analyzed). Similar observations have been made on 
primary cultures of human bronchial carcinoids treated 
with everolimus and pasireotide, although bronchial 
carcinoid cells are less responsive than pNETs cells to 
these agents as single treatments [48]. Lack of increase in 
the anti-proliferative effect of everolimus combined with 
octreotide has already been observed in the insulinoma rat 
cell line INS1, which is well sensitive to octreotide. In this 
cell line, both agents inhibit PI3K/Akt/mTOR pathway 
downstream of Akt through repression of TSC2, mTOR 
and p70S6K phosphorylation. Combined treatments did 
not enhance this effect, whereas Akt phosphorylation is 
not affected [31]. On the contrary, combined treatments 
of rapamycin and octreotide proved to be efficient in the 
pituitary cell line AtT20 and in human nonfunctioning 
pituitary adenoma cells in primary culture. In the AtT20 
cells, octreotide increases IRS-1 phosphorylation that 
was suppressed by rapamycin, subsequently decreasing 
rapamycin-dependent Akt activation triggering cell 
cycle arrest through an increase in p27/kip1 level [30]. 
In human pNET cells octreotide and pasireotide do not 
repress the PI3K/Akt/mTOR pathway neither affect 
ERK1/2 pathway, although they decrease cell viability. 
Therefore, these pathways do not consistently mediate 
SSAs efficacy. In combined treatments with everolimus, 
SSAs are not able to repress everolimus-dependent 
Akt activation. Moreover, SSAs-dependent caspases 
activation is reverted, suggesting that persistent high level 
of P-Akt in combined treatments may counteract the cell 
death machinery elicited by SSAs by phosphorylation 
and inactivation of pro-apoptotic components [43]. 
Meric-Bernstam et al. recently showed that high level 
of P-Akt (detected in everolimus pre- and on-treatment 
tumor biopsies) correlated with longer PFS of patients 
carrying NET. They concluded that increase in P-Akt 
under everolimus treatment is not a marker of everolimus 
resistance but rather a marker of everolimus sensitivity 
[22]. In this clinical trial, all patients received octreotide 
LAR co-treatment [49], suggesting that, octreotide cannot 
repress everolimus-dependent Akt activation in the tumors 
of patients in vivo. These data are consistent with our 
results on primary cultures of pNETs.
Whereas decrease in objective response rate 
in combined treatments of everolimus and octreotide 
in clinical trial [19] may result from loss in caspase-
dependent apoptosis observed in pNETs cells in primary 
culture, PFS is increased. This could be explained by 
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death after 
surgery NA
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16(b) 36 F 43(d) No non functioning 0/12N 5 1/10 G2 Yes No lost
17 66 F 50 No non functioning 0/2N 6 <1/10 G2
No 
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indirect mechanisms involving everolimus and SSAs-
induced inhibition of tumor angiogenesis that might 
contained tumor growth [50]. As a matter of fact, GEP-
NETs are highly vascularized tumors expressing several 
growth factors and their corresponding receptors [51]. 
Among them, GEP-NETs synthesize and secrete high 
level of vascular endothelial growth factor (VEGF), 
a potent pro-angiogenic factor [52]. High expression 
of VEGF correlated with increased angiogenesis and 
decreased PFS [53]. Both SSAs [54, 55] and rapalogs 
[56] impaired VEGF production and secretion in 
tumors cells and particularly in NET cells [57, 58]. 
Moreover, they have been shown to control key steps 
of the angiogenic process: endothelial cell proliferation, 
endothelial tubule formation [50, 56, 59–61] which 
could be involved in the PFS increase observed in 
SSA and everolimus combined treatments in clinical 
trials. In a phase III trial, sunitinib a multi-tyrosine 
kinase receptors inhibitor targeting the VEGF receptor 
improved PFS as compared to placebo in patients with 
advanced pNETs [62] and obtained approval from 
the FDA.
In conclusion, this study represents the first 
investigation of combined treatments of everolimus with 
octreotide or pasireotide in primary cultures of human 
pNET cells. It shows that everolimus and SSAs repress 
cell viability and CgA secretion in single treatment, 
however their efficacy is not improved in combined 
treatments. These results are consistent with clinical 
reports showing that combined treatment do not induce 
a marked benefit for patients compared to everolimus 
single treatment. Akt activation by everolimus, 
unchallenged by SSAs, and loss of caspase-dependent 
apoptosis induced by SSAs are molecular events 
that strongly support this limited benefit. During the 
processing of our manuscript, Falletta et al. established 
a link between everolimus-dependent cell viability 
of pNET primary cultures, active Akt/mTOR/4EBP 
basal levels in the initial tumor tissue and the clinical 
aggressiveness of the tumor (high Ki67 index) [63]. In 
our study, we cannot highlight any correlation between 
cell viability or CgA secretion responses to everolimus 
and/or SSAs treatments and the WHO grade or Ki67 
index of the initial tumor. Nevertheless, we observed 
good responses to everolimus or SSAs in some primary 
cultures from grade 3 tumors and/or Ki67≥10%. No 
correlation could be established between treatments 
responses and MEN1 mutations, PTEN or DAXX/ATRX 
expression levels. This suggested that these available 





























19(c) 64 M 26(d) No gastrinoma 0/30N <2% <1/50 G1 No PPI 5 years
20(a) 44 F 30 Yes non functioning 6/19N 2 NA G1 No
percutaneous 
thermoablation 2 years
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22 58 F 70 Yes gastrinoma 2/5N <2 NA G1 NA NA lost
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25 41 F 35 No non functioning 0/3N 5 6/10 G2 Yes No 1 year
Tumor size is expressed as maximal diameter (mm). For multiple localization, tumor size is the sum of each localization. (a) Tumor 
associated to MEN1 syndrome. (b) Tumor associated to VHL. (c) Patient treated with proton pump inhibitor (PPI) before surgery. (d) 
Multiple localization. NA (not available). N (lymph node). N: X/YN X positive nodes/Y analyzed nodes. Nx : no nodes were found in the 
resected specimen. Grade is determined according to WHO classification.
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of pNETs to everolimus or SSAs [64]. Finally, primary 
culture of pNETs is a suitable preclinical model to further 
define biological effects and underlying mechanisms 
for new or other inhibitors of signaling pathways (Ras/
raf/MEK, PI3K, IGF1R…) previously described as 
potentially promising for co-targeted therapy in NET cell 
lines [45, 46, 65–67].
PATIENTS AND METHODS
Patients
The present study was approved by the Ethics 
Committee of the Aix-Marseille University (Aix-
Marseille, France) and informed consent was obtained 
from each patient. Twenty five patients with pNET tumor 
were included in the study (Table 3). All the patients were 
bearing tumor requiring surgical removal. Patients were 
naïve of antitumor treatment before surgery. The only 
criterion for tumors selection was their identification 
as primary pNET or pNET derived metastasis by 
pathological analysis. Twenty four tumors were primary 
pNETs and one was a hepatic metastasis of a pNET. In 
22 cases, there was no clinical or biochemical evidence 
of hormonal hypersecretion, thus they were considered 
as nonfunctional pNETs. In 3 cases, the tumors were 
secreting and symptomatic: insulinoma (tumor 18), and 
gastrinoma (tumors 19,22), confirmed by pathology 
reports. Determination of Ki67 and proliferation index 
allowed grade classification (WHO 2010 classification) 
(Table 3).
Reagents
Everolimus, octreotide and pasireotide, were 
provided by Novartis (Novartis AG, Basel Switzerland). 
All other reagents were purchased from Sigma-Aldrich 
(St Quentin Fallavier, France). Stock solutions of 10-
2M everolimus were prepared in DMSO and kept at 
-80°C. Serial dilutions to obtain final concentrations of 
10nM to 0.1nM everolimus were done directly in the 
culture medium containing 5% Fetal calf serum (FCS) 
(corresponding final DMSO dilutions were from 106 
to 108 fold). Stock solutions of octreotide (10-3M) and 
pasireotide (10-2M) were prepared into phosphate saline 
buffer containing 0.1% bovine serum albumin and 0.01N 
acetic acid and kept at -80°C. Serial dilutions to obtain 
1nM octreotide or pasireotide were done in the culture 
medium containing 5% FCS. In combined treatments 
experiments, octreotide and pasireotide were diluted 
in the culture medium containing 5% FCS and DMSO 
(107 fold dilution) when used as single treatment (diluted 
in vehicle). Culture medium containing 5% FCS and 
DMSO (107 fold dilution) was used in control conditions 
(vehicle) in all the experiments containing everolimus. 
We have previously shown that 1nM octreotide or 
pasireotide were effective on pNET primary culture 
[20]. These concentrations are close to their blood 
plasma levels (range 2-6nM for octreotide and 4-15nM 
for pasireotide) in patients treated monthly with 30-
120mg octreotide LAR or 20-60mg pasireotide LAR 
respectively [25, 26].
Cell culture
Primary cultures of human pNETs were performed 
as previously described [20]. Tumor fragments of the 25 
human pNETs, obtained after surgery, were dissociated 
mechanically and enzymatically [68]. Tumor cells 
were seeded into 24- or 6-well plates (according to the 
experiments) coated with extracellular matrix (ECM) 
(from bovine endothelial corneal cells as previously 
described [68]). Cells were maintained in culture in 
D-Valine DMEM, supplemented with 10% fetal calf 
serum (FCS), penicillin (100 U/ml), streptomycin 
(100 µg/ml), and glutamine (100 U/ml), at 37°C in a 
water-saturated atmosphere containing 7% CO2. Cell 
viability determination and chromogranin A (CgA) 
secretion were carried out on cell cultures from 22 
and 20 tumors respectively. Other experiments were 
performed according to the quantity of available tumor 
cells after dissociation of each tumor (range: 1.5 106 to 
50 106 cells). The number of primary cultures used for 
each experiment is indicated in the figure legends. All the 
experiments were done in D-Valine DMEM containing 
5% FCS.
Genomic analysis of MEN1
Formalin-fixed, paraffin-embedded tissue sections 
(FFPE) of 5µm from 25 pNETs were used for DNA 
extraction. One to three slides from each pNET were 
extracted with the QIAamp DNA FFPE Tissue Kit 
(Qiagen, Courtaboeuf, France) according to the size of 
tumor section. Briefly, xylene was applied on the slide and 
paraffin embedded tumor was scratched into a microfuge 
tube containing xylene. Extraction was then performed 
according to the manufacturers’ protocol. Purity and 
concentration of DNA were assessed using a Nanodrop 
ND-1000.
The coding exons and exon-intron boundaries of 
the MEN1 gene (NM_003977.2) were PCR amplified 
and screened by direct sequencing using specific primers 
on an ABI 3500XLDx (Applied Biosystems). Genetic 
analysis was performed with variant reporter software and 
pathogenicity of allelic variations were evaluated in silico 
using a battery of different bioinformatics algorithms 
(Polyphen2, UMD-predictor and Alamut 2.2.0 software 
[69]. Only variants classified as probably pathogenic or 
pathogenic were considered (Table 1).
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Immunohistochemistry of PTEN, ATRX and 
DAXX
Immunohistochemical labeling was performed on 
4µm unstained slide sections from Tissue microarray 
(TMA). Slides were deparaffinized and subjected 
to antigen retrieval. Immunolabelings for ATRX 
(rabbit Anti-ATRX antibody, dilution 1/400 (Sigma-
Aldrich, Cat. # HPA001906)) and DAXX (rabbit Anti-
DAXX antibody, dilution 1/100 (Sigma-Aldrich, Cat. 
# HPA008736)) were performed on the automated 
Ventana. Immunolabeling for PTEN (mouse Anti-PTEN 
antibody, dilution 1/50 (Dako, Les Ulis, France, Cat. # 
6H2.1)) were performed on the automated Dako. The 
expression was scored using stromal cells as a positive 
internal control. For ATRX and DAXX, positive case 
was defined as nuclear staining within tumor cells 
and negative staining was defined as lacked nuclear 
immunolabeling. For PTEN, only cytoplasmic staining 
was studied: low cytoplasmic staining was defined as 1 
and moderate to intense cytoplasmic immunolabeling as 
2 and 3 respectively.
Real-time quantitative PCR
Total mRNAs were extracted from 3x105 cells using 
the RNeasy Microkit (Qiagen). SST2 receptor mRNAs 
were detected by real-time quantitative PCR using specific 
primers and probes as previously described [70]. To 
produce standard curve, cDNA construct was produced, 
verified by sequencing and linearized. The mRNA level 
of SST2 was normalized to the glucuronidase β (GUSβ) 
mRNA level, as previously described [70]. Results were 
expressed as copy of mRNA for the SST2 gene/copy of 
mRNA for GUSβ.
Cell viability
Cells from each tumor were seeded into 24-well 
plates (4×104 cells/well). After 24 h in culture, cells were 
treated or not with the different pharmacological agents, 
as indicated in the figure legends, for 72 h. The medium 
was recovered for CgA determination and cell viability 
was assayed by a luminescent assay (CellTiter Glo; 
Promega, Charbonnières les Bains, France) according to 
the manufacturer’s protocol. Results were expressed as 
percentages of the value for control cells (in the absence 
of treatment).
CgA secretion
CgA secretion was determined on the medium 
recovered from cell viability experiments after 72 h 
of treatment (see above). The recovered culture media 
were centrifuged at 400g and stored at -20°C. CgA was 
measured using an Elisa kit (Chromogranin A Elisa Kit, 
Dako) according to the manufacturer’s protocol. CgA 
values were normalized to the corresponding cell viability 
values. Results were expressed as percentages of the value 
for the control conditions.
Caspase activity determination
Cells from each tumor were seeded into 24-well 
plates (4×104 cells/well). After 24 h in culture, cells 
were treated with the different pharmacological agents 
for 24 h. The activity of the executioner caspases 3 and 
7 was measured using Caspase Glo 3/7 Assay (Promega) 
according to the manufacturer’s protocol. Results were 
expressed as a percentage of the value for the control 
conditions.
Protein extraction and western blotting
Cells from each tumor were seeded into 6-well 
plates (0.5x106 cells/well). After 24 h in culture, cells were 
treated or not with the different pharmacological agents, as 
indicated in the figure legends. Cells were then solubilized 
at 4°C for 15 min in a lysis buffer [25mM Tris (pH7.4), 
150 mM NaCl, 1% Nonidet P-40, 0.25% deoxycholate, 
1 mM EGTA, 1mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride (AEBSF), 1 mM Na3VO4, and 10 μg/ml leupeptin 
and aprotinin] as previously described [27]. Denatured 
proteins were separated on 10% SDS-PAGE and 
transferred to PVDF membrane (Perkin Elmer, France). 
Immunodetection of the β actin and the phosphorylated 
levels of Akt, ERK1/2 and p70S6K was performed using 
the mouse monoclonal anti-β-actin (Sigma-Aldrich, Cat. # 
A5441), the polyclonal phospho-AktSer473 (Cat. # 9271), 
phospho-p44/42ERK1/2 (Cat. # 9101), the monoclonal 
phospho-p70S6KThr389 (Cat. # 9234) rabbit antibodies 
respectively (New England Biolab, Ozyme, France) and 
an anti-mouse IgG or anti-Rabbit IgG coupled to alkaline 
phosphatase as the secondary antibody. Blots were 
developed with the enhanced chemiluminescence CDP-
Star™ detection system (Life Technologies, France) and 
quantified using Syngene and Genetools sofwares (Gbox, 
Ozyme, France). The total Akt, ERK1/2 and p70S6K 
content was systematically monitored by reprobing the 
membrane using the polyclonal Akt (Cat. # 9272), the 
monoclonal p70S6K (Cat. # 2708) rabbit antibodies (New 
England Biolab, Ozyme, France) and the polyclonal ERK1 
antiserum (Santa Cruz Biotechnology, Tebu, France, Cat. # 
sc-94). The relative expression of phospho-Akt, phospho-
ERK2 and phospho-p70S6K was calculated as a ratio to 
each total protein respectively and expressed in percent of 
the control value.
Statistical analysis
Each assay was performed in triplicate except for 
immunoblotting determinations. Results are presented as 
the mean ± SEM of at least three tumors. The statistical 
significance between groups was determined by the 
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paired Wilcoxon nonparametric test or Student’s t-test and 
unpaired Mann-Whitney test. To measure the strength of 
association between pairs of variables without specifying 
dependency, Spearman rank order correlations were run. 
To measure the link between two qualitative parameters, 
Chi square test was performed. Differences were 
considered statistically significant at p ≤ 0.05.
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